Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
- Comella, P
- Filippelli, G
- De Cataldis, G
- Massidda, B
- Frasci, G
- Maiorino, L
- Putzu, C
- Mancarella, S
- Palmeri, S
- Cioffi, R
- Buzzi, F
- Milia, V
- Gambardella, A
- Natale, D
- Bianco, M
- Ghiani, M
- Masullo, P.
- ROSELLI, MARIO
Publication date
February 2007
DOI Publisher
Oxford University Press Language
EnglishAbstract
Triplet regimens were occasionally reported to produce a higher response rate (RR) than doublets in locally advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was conducted to assess (i) whether the addition of cisplatin (CDDP) to either gemcitabine (GEM) and vinorelbine (VNR) or GEM and paclitaxel (PTX) significantly prolongs overall survival (OS) and (ii) to compare the toxicity of PTX-containing and VNR-containing combinations
Add to ORKG